Neuroinflammation represents a fundamental pathological mechanism that underlies virtually all neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), frontotemporal dementia (FTD), and multiple sclerosis (MS). This comprehensive page explores the molecular and cellular processes involved in neuroinflammation, their contribution to disease progression, and emerging therapeutic strategies aimed at modulating this deleterious inflammatory response. [@neuroinflammation_definition]
Unlike acute inflammation, which serves protective functions, chronic neuroinflammation becomes self-perpetuating and drives progressive neuronal loss. The inflammatory cascade involves the coordinated activation of resident glial cells—primarily microglia and astrocytes—along with peripheral immune cells that infiltrate the brain parenchyma. This activation leads to the release of pro-inflammatory cytokines, chemokines, reactive oxygen species (ROS), reactive nitrogen species (RNS), and lipid mediators that collectively orchestrate a destructive biochemical environment. [@microglial_activation]
Neuroinflammation represents a fundamental pathological mechanism that underlies virtually all neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), frontotemporal dementia (FTD), and multiple sclerosis (MS). This comprehensive page explores the molecular and cellular processes involved in neuroinflammation, their contribution to disease progression, and emerging therapeutic strategies aimed at modulating this deleterious inflammatory response. [@neuroinflammation_definition]
Unlike acute inflammation, which serves protective functions, chronic neuroinflammation becomes self-perpetuating and drives progressive neuronal loss. The inflammatory cascade involves the coordinated activation of resident glial cells—primarily microglia and astrocytes—along with peripheral immune cells that infiltrate the brain parenchyma. This activation leads to the release of pro-inflammatory cytokines, chemokines, reactive oxygen species (ROS), reactive nitrogen species (RNS), and lipid mediators that collectively orchestrate a destructive biochemical environment. [@microglial_activation]
Microglia are the resident innate immune cells of the central nervous system (CNS), originating from yolk sac progenitors during embryonic development. In the healthy brain, microglia exist in a surveillance state characterized by small cell bodies and highly ramified processes that continuously scan the surrounding environment. These cells express pattern recognition receptors (PRRs) including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and triggering receptor expressed on myeloid cells 2 (TREM2) that enable detection of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). [@trem2]
Upon encountering pathological stimuli, microglia undergo dramatic morphological and functional transformations, adopting distinct activation states:
The M1 phenotype represents the classically activated, pro-inflammatory state characterized by the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), interleukin-18 (IL-18), nitric oxide (NO), and ROS. These cells upregulate major histocompatibility complex (MHC) class II molecules and costimulatory signals, enabling antigen presentation. Prolonged M1 activation leads to microglial priming, a hyperresponsive state where subsequent inflammatory challenges trigger exaggerated responses.
The M2 phenotype represents the alternatively activated, anti-inflammatory state that promotes tissue repair and homeostasis. M2 microglia secrete neurotrophic factors including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and transforming growth factor-beta (TGF-beta). They express markers including CD206 (mannose receptor) and Arginase-1 (Arg1), and participate in debris clearance and wound healing.
Disease-Associated Microglia (DAM) represent a recently identified population that emerges in neurodegenerative conditions. DAM exhibit a distinct transcriptional signature characterized by upregulation of disease-specific genes including TREM2-dependent genes, APOE, and CST3. These cells appear to represent an attempt at compensation—attempting to clear pathological protein aggregates—but may become dysfunctional over time. [@trem2]
Astrocytes constitute the most abundant glial cell type in the human brain and play essential roles in maintaining CNS homeostasis. In response to neuroinflammation, astrocytes undergo a process termed reactive astrogliosis, characterized by upregulation of glial fibrillary acidic protein (GFAP), cellular hypertrophy, and proliferation. Reactive astrocytes adopt phenotypically distinct states that profoundly influence disease outcomes. [@astrocytes_neuroinflammation]
The A1 phenotype represents the neurotoxic reactive state induced by microglial-derived cytokines, particularly IL-1α, TNF-α, and C1q. A1 astrocytes upregulate complement components (C3, C4), release pro-inflammatory cytokines, and acquire the ability to eliminate synapses—contributing to the synaptic loss that characterizes neurodegeneration. These cells express markers including C3 and SerpinA3N, and their presence correlates with regions of neuronal loss.
The A2 phenotype represents the neuroprotective reactive state that promotes tissue repair. A2 astrocytes upregulate neurotrophic factors including BDNF, GDNF, and thrombospondins, and participate in blood-brain barrier (BBB) repair. They express markers including S100A10 and Emp1, and their presence correlates with regions of neuroprotection.
| Astrocyte Phenotype | Markers | Functions | Effect on Neurodegeneration |
|---------------------|---------|-----------|-----------------------------|
| A1 (Neurotoxic) | C3, C4, SerpinA3N | Pro-inflammatory cytokine release, complement synthesis, synapse elimination | Deleterious |
| A2 (Neuroprotective) | S100A10, Emp1, BDNF | Trophic factor release, BBB repair, anti-inflammatory mediator synthesis | Protective |
The blood-brain barrier (BBB) represents a critical interface between the peripheral circulation and the CNS. Under physiological conditions, the BBB restricts the entry of peripheral immune cells and molecules into the brain parenchyma. However, in neurodegenerative diseases, BBB dysfunction permits the infiltration of peripheral immune cells, contributing substantially to neuroinflammation. [@blood_brain_barrier]
BBB breakdown in neurodegeneration involves:
The resulting neuroimmune interface dysfunction creates a self-reinforcing cycle where neuroinflammation promotes further BBB breakdown, enabling additional peripheral immune cell entry.
Nuclear factor kappa B (NF-κB) serves as the central transcription factor governing the inflammatory response in neurodegeneration. The NF-κB family comprises five members (p65/RelA, RelB, c-Rel, p50/p105, p52/p100) that form homodimers and heterodimers with distinct transcriptional activities. In the CNS, NF-κB is activated by multiple stimuli relevant to neurodegeneration:
Activating stimuli:
The NLRP3 inflammasome represents a cytosolic protein complex that serves as a critical hub for IL-1β and IL-18 production in neurodegeneration. Unlike NF-κB, which regulates cytokine transcription, the NLRP3 inflammasome controls the proteolytic maturation and release of these potent inflammatory mediators. [@nlrp3_ad]
The inflammasome activation requires two distinct signals:
NLRP3 activators in neurodegeneration:
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway has recently emerged as a critical driver of neuroinflammation in neurodegeneration. Originally characterized as a sensor for foreign DNA (viral, bacterial), cGAS can also be activated by endogenous DNA released from damaged mitochondria, micronuclei, and cytosolic DNA. [@cgas_sting]
cGAS-STING activation in neurodegeneration:
Sources of endogenous cGAS activators:
The complement system has been recognized as a critical mediator of synapse loss in neurodegeneration. The complement cascade, originally characterized in peripheral immunity, operates in the CNS through microglial synthesis and local activation. [@complement_system]
Key complement components in neurodegeneration:
| Component | Function in Neurodegeneration |
|-----------|-------------------------------|
| C1q | Initiates complement cascade; tags synapses for elimination; binds directly to Aβ and tau |
| C3 | Central complement mediator; microglial chemoattractant; opsonizes synapses |
| C3a | Anaphylatoxin that recruits and activates microglia |
| C5a | Pro-inflammatory anaphylatoxin; contributes to neurotoxicity |
| C5b-9 (MAC) | Pores in neuronal membranes; directly contributes to cell death |
The complement pathway contributes to neuroinflammation through synapse elimination, a process that normally occurs during development but is pathologically reactivated in neurodegeneration. Microglia recognize C1q- and C3-opsonized synapses via complement receptors (CR3), leading to phagocytic removal. This mechanism explains the early synapse loss observed in AD and PD, preceding overt neuronal death. [@synapse_elimination]
NADPH oxidase (NOX) represents the primary enzymatic source of ROS in activated microglia. While ROS serve important physiological signaling functions, excessive NOX-derived ROS drive oxidative damage and amplify neuroinflammation. [@nadph_oxidase]
NOX isoforms in the brain:
Neuroinflammation in AD represents both an early driver and a consequence of amyloid and tau pathology. The relationship between protein aggregation and inflammation follows a bidirectional pattern:
Aβ-driven inflammation:
Neuroinflammation in PD follows a similarly bidirectional relationship with alpha-synuclein pathology. The substantia nigra pars compacta exhibits pronounced microglial activation that correlates with dopaminergic neuron loss.
Alpha-synuclein-driven inflammation:
Gut-brain axis in PD neuroinflammation:
Neuroinflammation in ALS follows a non-cell autonomous pattern where motor neuron death results from dysfunction in neighboring glial cells. Both sporadic and familial ALS feature prominent neuroinflammation.
Key inflammatory mechanisms in ALS:
In MS, neuroinflammation represents the primary disease mechanism rather than a secondary phenomenon. The disease involves autoimmune T cell and B cell responses against myelin antigens.
Inflammatory features in MS:
TNF-α represents the most prominent pro-inflammatory cytokine in neurodegeneration, serving as both a trigger and an executor of neurotoxicity. [@tnf_alpha]
Sources in CNS:
IL-1β contributes substantially to neuroinflammation through multiple mechanisms. Unlike TNF-α, IL-1β requires processing by caspase-1, making the NLRP3 inflammasome a critical therapeutic target. [@il1_beta]
Functions in neurodegeneration:
IL-6 exhibits both pro-inflammatory and neuroprotective properties, depending on context. Chronic IL-6 elevation correlates with cognitive decline. [@cognitive_decline]
Functions:
| Target | Mechanism | Agent/Approach | Status |
|--------|-----------|----------------|--------|
| NLRP3 | Inflammasome inhibition | MCC950, Dapansutrile | Preclinical/Phase I |
| TREM2 | Enhance phagocytosis | Anti-TREM2 antibodies | Phase I/II |
| CSF1R | Microglial modulation | PLX3397, PLX5622 | Preclinical |
| CD20 | B cell depletion | Ocrelizumab | Approved for MS |
| Complement C1q | Block synapse elimination | ANX005 | Phase I |
| IL-1R | Receptor blockade | Anakinra, Canakinumab | Phase II |
| TNF-α | Neutralization | Etanercept | Phase II (inconclusive) |
| COX-2 | Reduce prostaglandins | Celecoxib | Phase III (failed) |
| Minocycline | Broad microglial inhibition | Tetracycline | Phase III (failed) |
| CX3CR1 | Fractalkine receptor | CX3CR1 agonists | Preclinical |
Emerging approaches:
CSF biomarkers:
Neuroinflammation represents a unified pathological mechanism across neurodegenerative diseases, characterized by chronic activation of microglia and astrocytes, pro-inflammatory cytokine release, complement-mediated synapse loss, and progressive neuronal dysfunction. While the specific triggers differ between diseases—Aβ and tau in AD, α-synuclein in PD, mutant SOD1/TDP-43 in ALS—the downstream inflammatory pathways converge on common mechanisms that offer therapeutic opportunities.
The challenge lies in developing interventions that dampen harmful neuroinflammation while preserving essential immune surveillance functions. Targeting specific pathways including NLRP3, TREM2, and complement components, rather than broadly suppressing immune responses, offers the most promising approach. As our understanding of the complex neuroimmune interface deepens, precision modulation of specific inflammatory pathways may provide meaningful disease modification for the many neurodegenerative conditions that currently lack effective treatments.